Chemistry:25D-NBOMe

From HandWiki
Revision as of 19:37, 5 February 2024 by Scavis2 (talk | contribs) (fixing)
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Short description: Chemical compound
25D-NBOMe
25D-NBOMe2DACS.svg
Legal status
Legal status
  • BR: F2
  • DE: NpSG (Industrial and scientific use only)
  • UK: Class A
  • Illegal in China and Sweden
Identifiers
CAS Number
PubChem CID
ChemSpider
UNII
Chemical and physical data
FormulaC19H25NO3
Molar mass315.413 g·mol−1
3D model (JSmol)

25D-NBOMe (or NBOMe-2C-D) is a derivative of the phenethylamine derived hallucinogen 2C-D. It acts in a similar manner to related compounds such as 25I-NBOMe, which is a potent agonist at the 5-HT2A receptor.[1][2] 25D-NBOMe has been sold as a street drug since 2010 and produces similar effects in humans to related compounds such as 25I-NBOMe and 25C-NBOMe.[3] It was banned as a Temporary Class Drug in the UK on 10 June 2013 after concerns about its recreational use.[4]

Toxicity and harm potential

Neurotoxic and cardiotoxic actions

Emergency treatment

Legality

China

As of October 2015 25D-NBOMe is a controlled substance in China.[5]

Sweden

Sveriges riksdag added 25D-NBOMe to schedule I ("substances, plant materials and fungi which normally do not have medical use") as narcotics in Sweden as of Aug 1, 2013, published by Medical Products Agency in their regulation LVFS 2013:15 listed as 25D-NBOMe 2-(2,5-dimetoxi-4-metylfenyl)-N-(2-metoxibensyl)etanamin.[6]

United Kingdom

This substance is a Class A drug in the United Kingdom as a result of the N-benzylphenethylamine catch-all clause in the Misuse of Drugs Act 1971.[7]


United States

Unregulated at a federal and state level, though arguably may contravene the Federal Analog Act under certain circumstances given its structural and functional similarity to controlled substance 2C-D.

See also

Notes

References

  1. "Synthesis and structure-activity relationships of N-benzyl phenethylamines as 5-HT2A/2C agonists". ACS Chemical Neuroscience 5 (3): 243–9. March 2014. doi:10.1021/cn400216u. PMID 24397362. 
  2. Hansen M (2010-12-16). Design and Synthesis of Selective Serotonin Receptor Agonists for Positron Emission Tomography Imaging of the Brain (Ph.D. thesis). University of Copenhagen. doi:10.13140/RG.2.2.33671.14245.
  3. "Characterization of Eleven 2,5-Dimethoxy-N-(2-methoxybenzyl)phenethylamine (NBOMe) Derivatives and Differentiation from their 3- and 4-Methoxybenzyl Analogues - Part I". Microgram Journal 9 (2): 84–109. 2012. https://www.dea.gov/pr/microgram-journals/2012/mj9_84-109.pdf. Retrieved 14 January 2014. 
  4. "Temporary class drug order report on 5-6APB and NBOMe compounds". UK Home Office. 4 Jun 2013. https://www.gov.uk/government/publications/temporary-class-drug-order-report-on-benzofury-and-nbome-compounds. 
  5. "关于印发《非药用类麻醉药品和精神药品列管办法》的通知" (in Chinese). China Food and Drug Administration. 27 September 2015. http://www.sfda.gov.cn/WS01/CL0056/130753.html. 
  6. "Läkemedelsverkets författningssamling" (in Swedish). Läkemedelsverkets. https://lakemedelsverket.se/upload/lvfs/LVFS_2013-15.pdf. 
  7. "The Misuse of Drugs Act 1971 (Ketamine etc.) (Amendment) Order 2014" (in en). http://www.legislation.gov.uk/uksi/2014/1106/made.